Muscle Relaxant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Type of Drugs (Facial Muscle Relaxants, Skeletal muscle Relaxants, and Neuromuscular Blocking Agents), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Market Snapshot

Muscle Relaxant Drugs Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Growing geriatric populations worldwide who are more prone to musculoskeletal disorders is the major factor driving the growth of the market studied. Additionally, increasing prevalence of pain and spasm conditions, increasing focus on the development of novel drugs for the treatment of spasm and pain, frequent product approvals, and growing number of surgeries are the other factors that are bolstering the market growth. However, side effects associated with the muscle relaxant drugs are acting as a restraining factor to the market growth.

Scope of the Report

Muscle relaxants are a distinct group of medications used to relax or reduce tension in the muscle. Baclofen, methocarbamol, and tizanidine are the few muscle relaxant drugs that work in the brain or spinal cord to block over-excited neuronal pathways. Other relaxants, such as dantrolene and botulinum toxin, act directly on the muscle. Muscle relaxants mainly treat two major conditions: spasticity (stiff, rigid muscles) caused by conditions such as cerebral palsy, multiple sclerosis, and stroke. Secondly, muscle spasms are typically temporary and associated with conditions such as tension headache, low back pain, or fibromyalgia.

By Type of Drugs
Facial Muscle Relaxants
Skeletal muscle Relaxants
Neuromuscular Blocking Agents
By Dristibution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Neuromuscular Blocking Agents Segment Holds Significant Share in Muscle Relaxant Drugs Market

Neuromuscular blocking agents are the potent muscle relaxants typically used only during surgery to prevent muscle movement. They are structurally related to acetylcholine, the main neurotransmitter in the body, and they cause muscle relaxation by binding to acetylcholine receptors postsynaptically (preventing acetylcholine from binding). This blocks neuromuscular transmission and causes paralysis of the muscle.

These are of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents), or noncompetitive, depolarizing agents (neuromuscular depolarizing agents).

Cisatracurium, Succinylcholine, Doxacurium, and Rocuronium are the few examples of Neuromuscular blocking agents. In November 2019, Zydus Cadila had U.S.FDA approval for its generic version of muscle relaxant Cisatracurium Besylate Injection with strengths of 10 mg/5 ml and 200 mg/20 ml given before general anesthesia.

Picture3Muscle Relaxant Drugs.png

North America Dominates the Global Muscle Relaxant Drugs Market

The current growth of the North America Muscle Relaxant Drugs market can be primarily attributed to the increasing prevalence of musculoskeletal disorders. On the other side, the presence of sophisticated healthcare infrastructure, frequent product approvals, the presence of major market players focusing on the development of novel molecules for the treatment of pain, and spasm are also acting as major factors for the growth of the market.

According to Palmer College of Chiropractic commissioned Gallup research study in 2018, Neck and back pain is common among adults in the United States. About two-thirds of US adults (62%) have had neck or back pain. In March 2017, Zydus Cadila received approval from the USFDA to market tizanidine hydrochloride capsules, a muscle relaxant, in the American market.

Picture2Muscle Relaxant Drugs Market.png

Competitive Landscape

In the market studied, major players focus on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, and acquisitions and mergers. Key developments of the market include - in September 2019, Ipsen Biopharmaceuticals received United States Food and Drug Administration approval of expanded use of Dysport (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Geriatric Population

      2. 4.2.2 Increasing Prevalence of Musculoskeletal Disorders

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects of Muscle Relaxants

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Drugs

      1. 5.1.1 Facial Muscle Relaxants

      2. 5.1.2 Skeletal muscle Relaxants

      3. 5.1.3 Neuromuscular Blocking Agents

    2. 5.2 By Dristibution Channel

      1. 5.2.1 Hospital Pharmacy

      2. 5.2.2 Retail Pharmacy

      3. 5.2.3 Online Pharmacy

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Acorda Therapeutics

      2. 6.1.2 Dr Reddy's laboratories

      3. 6.1.3 Ipsen Biopharmaceuticals Inc.

      4. 6.1.4 Lannett

      5. 6.1.5 Neurana Pharmaceuticals

      6. 6.1.6 Pfizer

      7. 6.1.7 Teva Pharmaceuticals

      8. 6.1.8 Unichem Laboratories

      9. 6.1.9 Zydus Cadila

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Development

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Muscle Relaxant Drugs Market market is studied from 2018 - 2026.

The Muscle Relaxant Drugs Market is growing at a CAGR of 5.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Neurana Pharmaceuticals, Pfizer, Teva Pharmaceuticals, Zydus Cadila, Ipsen Biopharmaceuticals Inc. are the major companies operating in Muscle Relaxant Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!